References
- Aungst B. J., Meyers M. J., Shefter E., Shami E. G. Prodrugs for improved oral nalbuphine bioavailability: inter‐species differences in the disposition of nalbuphine and its acetylsalicylate and anthranilate esters. International Journal of Pharmaceutics 1987; 38: 19–209
- Errick J. K., Heel R. C. Nalbuphine—a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 1983; 26: 191–211
- Iwamoto K., Klaassen C. D. First‐pass effect of morphine in rats. Journal of Pharmacology and Experimental Therapeutics 1977; 200: 236–244
- Lo M. ‐W., Jeurgens G. P., Whitney C. C., Jr. Determination of nalbuphine in human plasma by automated high‐performance liquid chromatography with electrochemical detection. Research Communications in Chemistry, Pathology and Pharmacology 1984; 43: 159–168
- Lo M. ‐W., Schary W. L., Whitney C. C., Jr. The disposition and bioavailability of intravenous and oral nalbuphine in healthy volunteers. The Journal of Clinical Pharmacology 1987; 27: 866–873
- Misra A. L. Metabolism of Opiates. Factors Effecting the Action of Narcotics, M. L. Adler, L. Manara, R. Samanin. Raven Press, New York 1978; 297–343
- Pieniaszek H. J., Jr., Aungst B. J., Adams M. P., Davidson A. F., Whitney C. C., Jr., Myers M. J., Shefter E. Disposition and oral bioavailability of nalbuphine and its anthranilate ester prodrug in the rat, dog and human. Abstracts from the Japanese‐United States Congress of Pharmaceutical Sciences. 1987; 91
- Wong Y. N., Lo M. ‐W., Whitney C. C., Croft J. E. Comparison of in vitro and in vivo nalbuphine metabolism. The Pharmacologist 1986; 28: 212